The Phase I clinical trial will asset the treatment’s ability to potentially treat inflammatory bowel disease. Credit: meeboonstudio/Shutterstock.

Spyre Therapeutics has dosed the first subjects in the Phase I clinical trial of SPY001 to potentially treat inflammatory bowel disease (IBD).

The placebo-controlled, double-blind trial is set to enrol approximately 48 healthy adult participants. It will have four single-ascending dose (SAD) and two multi-ascending dose (MAD) cohorts.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Safety is the trial’s primary endpoint while pharmacokinetics is the secondary endpoint.

The company anticipates reporting interim safety and pharmacokinetic data from the trial by the end of this year.

Based on the data from the Phase I trial, Spyre will advance the asset into the Phase II development stage next year.

SPY001 is a half-life extended anti-α4β7 monoclonal antibody.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

It has shown promise in preclinical studies, demonstrating equivalent potency to vedolizumab in blocking MadCAM-1 adhesion.

In addition, it exhibited a significantly longer half-life, suggesting the potential for less frequent dosing, possibly once every two or three months.

Spyre Therapeutics CEO Cameron Turtle said: “SPY001 is the first of our programmes across three of the most impactful mechanisms in IBD, namely α4β7, TL1A, and IL-23, all of which are expected to enter the clinic within the next 12 months.

“We look forward to highlighting interim data for SPY001 by the end of this year, which we expect will confirm that SPY001 is well tolerated with a half-life that enables a convenient Q8-12W subcutaneous dosing schedule, with interim data for our T1LA programme to follow.”

In November last year, Aeglea BioTherapeutics announced its name change to Spyre Therapeutics. This move was in line with the acquisition of Spyre Therapeutics by Aeglea BioTherapeutics in June.